Pomalidomide, a bone marrow cancer drug, may be safely repurposed to treat a rare genetic blood disorder, according to a recent clinical trial.
The Cleveland Clinic-led clinical trial was stopped early after demonstrating safety and effectiveness in treating hereditary hemorrhagic telangiectasia (HHT), a condition that currently has no cure.
